Clinical Trial Update: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC [Phase 3]

View source ↗

Summary

Novartis is running a Phase 3 trial comparing AAA817 combined with an androgen receptor pathway inhibitor (ARPI) versus standard of care in adults with PSMA-pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AAA817
• ARPI (androgen receptor pathway inhibitor) (androgen receptor pathway inhibitor)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: RECRUITING